Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group

Schizophrenia Clinical Trial

Official title:

Preventive and Personalized Medicine (2021-2023)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05090644
• Other study ID #: 1203
• Status: Completed
• Start date: March 30, 2022
• Est. completion date: January 20, 2023

Study information

• Verified date: March 2023
• Source: Asfendiyarov Kazakh National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Description:

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 700
• Est. completion date: January 20, 2023
• Est. primary completion date: January 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• persons of Kazakh nationality having this ethnicity in the 3rd generation

• age from 18 to 65 years old;

• the dispensary in a psychiatric institution at the place of residence with a diagnosis of "Paranoid schizophrenia";

• the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision):

• absence of severe and chronic somatic diseases;

• absence of severe and chronic neurological diseases;

• absence of comorbid drug addiction pathology;

• signed informed consent to conduct this study

Exclusion Criteria:

• persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation

• age less than 18 years old and over 65 years old;

• those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 "Paranoid schizophrenia";

• having a disease duration of less than 1 year (from the moment of taking under dispensary supervision):

• having severe and chronic somatic diseases;

• having severe and chronic neurological diseases;

• having comorbid narcological pathology;

• not signed informed consent to conduct this study

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Genetic:
• DNA analysis
GWAS

Locations

Country	Name	City	State
Kazakhstan	Republican Scientific and Practical Center for Mental Health	Almaty

Sponsors (1)

Lead Sponsor	Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of SNPs associated with schizophrenia	Using GWAS to identify candidate genes associate with schizophrenia	1 year